{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T03:28:46Z","timestamp":1786678126816,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFA1306002"],"award-info":[{"award-number":["2024YFA1306002"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFA1802700"],"award-info":[{"award-number":["2024YFA1802700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFA1803504"],"award-info":[{"award-number":["2024YFA1803504"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32230054"],"award-info":[{"award-number":["32230054"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32400635"],"award-info":[{"award-number":["32400635"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92357301"],"award-info":[{"award-number":["92357301"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-026-02988-9","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:42:40Z","timestamp":1781066560000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncometabolite 2-hydroxyglutarate destabilizes CDH1 to regulate quiescence and enhance chemotherapy sensitivity"],"prefix":"10.1186","volume":"24","author":[{"given":"Hai-Hui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Tian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Lei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Yuan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Zi","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"2988_CR1","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nature10898","volume":"483","author":"P Koivunen","year":"2012","unstructured":"Koivunen P, Lee S, Duncan CG, et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature. 2012;483:484\u20138.","journal-title":"Nature"},{"key":"2988_CR2","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nature08617","volume":"462","author":"L Dang","year":"2009","unstructured":"Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739\u201344.","journal-title":"Nature"},{"key":"2988_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1126\/science.1170944","volume":"324","author":"S Zhao","year":"2009","unstructured":"Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 2009;324:261\u20135.","journal-title":"Science"},{"key":"2988_CR4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nature10866","volume":"483","author":"S Turcan","year":"2012","unstructured":"Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012;483:479\u201383.","journal-title":"Nature"},{"key":"2988_CR5","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nature10860","volume":"483","author":"C Lu","year":"2012","unstructured":"Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483:474\u20138.","journal-title":"Nature"},{"key":"2988_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41588-017-0001-z","volume":"50","author":"S Turcan","year":"2018","unstructured":"Turcan S, Makarov V, Taranda J, et al. Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence. Nat Genet. 2018;50:62\u201372.","journal-title":"Nat Genet"},{"key":"2988_CR7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ccell.2018.04.011","volume":"34","author":"MS Waitkus","year":"2018","unstructured":"Waitkus MS, Diplas BH, Yan H. Biological Role and Therapeutic Potential of IDH Mutations in Cancer. Cancer Cell. 2018;34:186\u201395.","journal-title":"Cancer Cell"},{"key":"2988_CR8","first-page":"vdae78","volume":"6","author":"I Esparragosa Vazquez","year":"2024","unstructured":"Esparragosa Vazquez I, Sanson M, Chinot OL, et al. Olaparib in recurrent isocitrate dehydrogenase mutant high-grade glioma: A phase 2 multicenter study of the POLA Network. Neurooncol Adv. 2024;6:vdae78.","journal-title":"Neurooncol Adv"},{"key":"2988_CR9","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/s41419-019-1984-4","volume":"10","author":"T Wang","year":"2019","unstructured":"Wang T, Liang J, Zhang C, et al. The oncometabolite 2-hydroxyglutarate produced by mutant IDH1 sensitizes cells to ferroptosis. Cell Death Dis. 2019;10:755.","journal-title":"Cell Death Dis"},{"key":"2988_CR10","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nm.3788","volume":"21","author":"SM Chan","year":"2015","unstructured":"Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015;21:178\u201384.","journal-title":"Nat Med"},{"key":"2988_CR11","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1016\/j.molcel.2023.10.020","volume":"83","author":"R Foy","year":"2023","unstructured":"Foy R, Crozier L, Pareri AU, et al. Oncogenic signals prime cancer cells for toxic cell overgrowth during a G1 cell cycle arrest. Mol Cell. 2023;83:4047\u201361.","journal-title":"Mol Cell"},{"key":"2988_CR12","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41568-022-00450-9","volume":"22","author":"L Wang","year":"2022","unstructured":"Wang L, Lankhorst L, Bernards R. Exploiting senescence for the treatment of cancer. Nat Rev Cancer. 2022;22:340\u201355.","journal-title":"Nat Rev Cancer"},{"key":"2988_CR13","doi-asserted-by":"crossref","unstructured":"Radic M, Vlasic I, Jazvinscak Jembrek M, et al. Characterization of Vemurafenib-Resistant Melanoma Cell Lines Reveals Novel Hallmarks of Targeted Therapy Resistance. Int J Mol Sci 2022;23(17):9876.","DOI":"10.3390\/ijms23179910"},{"key":"2988_CR14","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1016\/j.cell.2022.03.033","volume":"185","author":"P Baldominos","year":"2022","unstructured":"Baldominos P, Barbera-Mourelle A, Barreiro O, et al. Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche. Cell. 2022;185:1694\u2013708.","journal-title":"Cell"},{"key":"2988_CR15","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13059-023-02963-4","volume":"24","author":"AJ Wiecek","year":"2023","unstructured":"Wiecek AJ, Cutty SJ, Kornai D, et al. Genomic hallmarks and therapeutic implications of G0 cell cycle arrest in cancer. Genome Biol. 2023;24:128.","journal-title":"Genome Biol"},{"key":"2988_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41556-024-01582-w","volume":"27","author":"M Mitra","year":"2025","unstructured":"Mitra M, Batista SL, Coller HA. Transcription factor networks in cellular quiescence. Nat Cell Biol. 2025;27:14\u201327.","journal-title":"Nat Cell Biol"},{"key":"2988_CR17","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.devcel.2020.05.006","volume":"53","author":"L Yue","year":"2020","unstructured":"Yue L, Wan R, Luan S, et al. Dek Modulates Global Intron Retention during Muscle Stem Cells Quiescence Exit. Dev Cell. 2020;53:661\u201376.","journal-title":"Dev Cell"},{"key":"2988_CR18","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.tcb.2019.05.002","volume":"29","author":"S Tumpel","year":"2019","unstructured":"Tumpel S, Rudolph KL, Quiescence. Good and Bad of Stem Cell Aging. Trends Cell Biol. 2019;29:672\u201385.","journal-title":"Trends Cell Biol"},{"key":"2988_CR19","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1016\/j.celrep.2017.09.007","volume":"20","author":"JS Kwon","year":"2017","unstructured":"Kwon JS, Everetts NJ, Wang X, et al. Controlling Depth of Cellular Quiescence by an Rb-E2F Network Switch. Cell Rep. 2017;20:3223\u201335.","journal-title":"Cell Rep"},{"key":"2988_CR20","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/s41418-022-00988-z","volume":"29","author":"K Engeland","year":"2022","unstructured":"Engeland K. Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ. 2022;29:946\u201360.","journal-title":"Cell Death Differ"},{"key":"2988_CR21","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13287-019-1219-8","volume":"10","author":"B Li","year":"2019","unstructured":"Li B, Sun C, Sun J, et al. Autophagy mediates serum starvation-induced quiescence in nucleus pulposus stem cells by the regulation of P27. Stem Cell Res Ther. 2019;10:118.","journal-title":"Stem Cell Res Ther"},{"key":"2988_CR22","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1016\/j.physa.2011.05.009","volume":"390","author":"SA Mench\u00f3n","year":"2011","unstructured":"Mench\u00f3n SA, Condat CA. Quiescent cells: A natural way to resist chemotherapy. Physica A. 2011;390:3354\u201361.","journal-title":"Physica A"},{"key":"2988_CR23","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/cas.12958","volume":"107","author":"S Takeishi","year":"2016","unstructured":"Takeishi S, Nakayama KI. To wake up cancer stem cells, or to let them sleep, that is the question. Cancer Sci. 2016;107:875\u201381.","journal-title":"Cancer Sci"},{"key":"2988_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde PS, Chen DS. Top 10 Challenges in Cancer Immunotherapy. Immunity. 2020;52:17\u201335.","journal-title":"Immunity"},{"key":"2988_CR25","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ccell.2020.01.007","volume":"37","author":"B Salvador-Barbero","year":"2020","unstructured":"Salvador-Barbero B, Alvarez-Fernandez M, Zapatero-Solana E, et al. CDK4\/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma. Cancer Cell. 2020;37:340\u201353.","journal-title":"Cancer Cell"},{"key":"2988_CR26","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/ncb0708-755","volume":"10","author":"JR Skaar","year":"2008","unstructured":"Skaar JR, Pagano M. Cdh1: a master G0\/G1 regulator. Nat Cell Biol. 2008;10:755\u20137.","journal-title":"Nat Cell Biol"},{"key":"2988_CR27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1101\/gad.285404","volume":"18","author":"KG Wirth","year":"2004","unstructured":"Wirth KG, Ricci R, Gimenez-Abian JF, et al. Loss of the anaphase-promoting complex in quiescent cells causes unscheduled hepatocyte proliferation. Genes Dev. 2004;18:88\u201398.","journal-title":"Genes Dev"},{"key":"2988_CR28","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1158\/0008-5472.CAN-22-3346","volume":"83","author":"J Su","year":"2023","unstructured":"Su J, Li R, Chen Z, et al. N 6-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer. Cancer Res. 2023;83:3059\u201376.","journal-title":"Cancer Res"},{"key":"2988_CR29","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1182\/blood-2016-07-726216","volume":"129","author":"J Ishizawa","year":"2017","unstructured":"Ishizawa J, Sugihara E, Kuninaka S, et al. FZR1 loss increases sensitivity to DNA damage and consequently promotes murine and human B-cell acute leukemia. Blood. 2017;129:1958\u201368.","journal-title":"Blood"},{"key":"2988_CR30","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","volume":"361","author":"ER Mardis","year":"2009","unstructured":"Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361:1058\u201366.","journal-title":"N Engl J Med"},{"key":"2988_CR31","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1126\/science.1164382","volume":"321","author":"DW Parsons","year":"2008","unstructured":"Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807\u201312.","journal-title":"Science"},{"key":"2988_CR32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1084\/jem.20092506","volume":"207","author":"S Gross","year":"2010","unstructured":"Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010;207:339\u201344.","journal-title":"J Exp Med"},{"key":"2988_CR33","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","volume":"17","author":"PS Ward","year":"2010","unstructured":"Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17:225\u201334.","journal-title":"Cancer Cell"},{"key":"2988_CR34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","volume":"19","author":"W Xu","year":"2011","unstructured":"Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19:17\u201330.","journal-title":"Cancer Cell"},{"key":"2988_CR35","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/embor.2011.43","volume":"12","author":"R Chowdhury","year":"2011","unstructured":"Chowdhury R, Yeoh KK, Tian Y, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 2011;12:463\u20139.","journal-title":"EMBO Rep"},{"key":"2988_CR36","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","volume":"148","author":"GL Semenza","year":"2012","unstructured":"Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148:399\u2013408.","journal-title":"Cell"},{"key":"2988_CR37","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2008.04.009","volume":"30","author":"WGJ Kaelin","year":"2008","unstructured":"Kaelin WGJ, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008;30:393\u2013402.","journal-title":"Mol Cell"},{"key":"2988_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41422-023-00864-6","volume":"34","author":"Y Mao","year":"2024","unstructured":"Mao Y, Zhang J, Zhou Q, et al. Hypoxia induces mitochondrial protein lactylation to limit oxidative phosphorylation. Cell Res. 2024;34:13\u201330.","journal-title":"Cell Res"},{"key":"2988_CR39","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41581-019-0182-z","volume":"15","author":"J Schodel","year":"2019","unstructured":"Schodel J, Ratcliffe PJ. Mechanisms of hypoxia signalling: new implications for nephrology. Nat Rev Nephrol. 2019;15:641\u201359.","journal-title":"Nat Rev Nephrol"},{"key":"2988_CR40","doi-asserted-by":"publisher","first-page":"9949","DOI":"10.1074\/jbc.RA118.007181","volume":"294","author":"Y Xu","year":"2019","unstructured":"Xu Y, Gao Q, Xue Y, et al. Prolyl hydroxylase 3 stabilizes the p53 tumor suppressor by inhibiting the p53-MDM2 interaction in a hydroxylase-independent manner. J Biol Chem. 2019;294:9949\u201358.","journal-title":"J Biol Chem"},{"key":"2988_CR41","doi-asserted-by":"publisher","first-page":"9885","DOI":"10.18632\/oncotarget.14241","volume":"8","author":"N Kozlova","year":"2017","unstructured":"Kozlova N, Wottawa M, Katschinski DM, et al. Hypoxia-inducible factor prolyl hydroxylase 2 (PHD2) is a direct regulator of epidermal growth factor receptor (EGFR) signaling in breast cancer. Oncotarget. 2017;8:9885\u201398.","journal-title":"Oncotarget"},{"key":"2988_CR42","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1080\/21691401.2019.1638793","volume":"47","author":"J Zhang","year":"2019","unstructured":"Zhang J, Si J, Gan L, et al. Research progress on therapeutic targeting of quiescent cancer cells. Artif Cells Nanomed Biotechnol. 2019;47:2810\u201320.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"2988_CR43","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41568-020-0263-0","volume":"20","author":"TG Phan","year":"2020","unstructured":"Phan TG, Croucher PI. The dormant cancer cell life cycle. Nat Rev Cancer. 2020;20:398\u2013411.","journal-title":"Nat Rev Cancer"},{"key":"2988_CR44","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1042\/BJ20040620","volume":"381","author":"JH Marxsen","year":"2004","unstructured":"Marxsen JH, Stengel P, Doege K, et al. Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases. Biochem J. 2004;381:761\u20137.","journal-title":"Biochem J"},{"key":"2988_CR45","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1091\/mbc.11.5.1555","volume":"11","author":"ER Kramer","year":"2000","unstructured":"Kramer ER, Scheuringer N, Podtelejnikov AV, et al. Mitotic regulation of the APC activator proteins CDC20 and CDH1. Mol Biol Cell. 2000;11:1555\u201369.","journal-title":"Mol Biol Cell"},{"key":"2988_CR46","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nature14471","volume":"522","author":"L Chang","year":"2015","unstructured":"Chang L, Zhang Z, Yang J, et al. Atomic structure of the APC\/C and its mechanism of protein ubiquitination. Nature. 2015;522:450\u20134.","journal-title":"Nature"},{"key":"2988_CR47","doi-asserted-by":"publisher","first-page":"eaat5685","DOI":"10.1126\/sciadv.aat5685","volume":"4","author":"K Sajiki","year":"2018","unstructured":"Sajiki K, Tahara Y, Uehara L, et al. Genetic regulation of mitotic competence in G(0) quiescent cells. Sci Adv. 2018;4:eaat5685.","journal-title":"Sci Adv"},{"key":"2988_CR48","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1074\/jbc.M115.688762","volume":"291","author":"T Laukka","year":"2016","unstructured":"Laukka T, Mariani CJ, Ihantola T, et al. Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes. J Biol Chem. 2016;291:4256\u201365.","journal-title":"J Biol Chem"},{"key":"2988_CR49","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41556-022-00853-8","volume":"24","author":"L Chen","year":"2022","unstructured":"Chen L, Morcelle C, Cheng Z, et al. Itaconate inhibits TET DNA dioxygenases to dampen inflammatory responses. Nat Cell Biol. 2022;24:353\u201363.","journal-title":"Nat Cell Biol"},{"key":"2988_CR50","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41467-019-13668-3","volume":"11","author":"I Martinez-Reyes","year":"2020","unstructured":"Martinez-Reyes I, Chandel NS. Mitochondrial TCA cycle metabolites control physiology and disease. Nat Commun. 2020;11:102.","journal-title":"Nat Commun"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-02988-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02988-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02988-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T02:59:32Z","timestamp":1786676372000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-02988-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2988"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-02988-9","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All glioma samples were acquired from Affiliated Huashan Hospital of Fudan University. A physician or nurse practitioner obtained informed consent from the patients. The procedures related to human subjects were approved by Ethic Committee of the Institutes of Biomedical Sciences (IBS), Fudan University.All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"443"}}